News | Proton Therapy | January 29, 2020

IBA Signs Contract to Install Georgia’s First Proton Therapy Center

IBA ProteusOne proton therapy system

January 29, 2020 — IBA (Ion Beam Applications S.A.) announced that it has signed a contract and received a major down payment for a ProteusONE solution financed by the International Charity Foundation Cartu, a charity organization in Georgia. The contract includes a clinical ProteusONE solution and an additional cyclotron that will be dedicated to scientific research. The proton therapy center will be installed at the campus of the new Kutaisi International University (KIU), located in Kutaisi, Ga., and the first patient treatment is scheduled for 2024.

The contract includes a long-term operation and maintenance agreement and the typical end-user price for a ProteusONE solution with a maintenance contract is between EUR 35 and 40 million. IBA has begun to recognize revenue for the contract in the 2019 financial year.

Including this order, IBA sold eight rooms in 2019, bringing its backlog to a record high of EUR 1.1 billion. The Company has also finalized the refinancing of its credit lines with a term loan facility and a revolving loan facility for a total of EUR 67 million, further strengthening its balance sheet and its capacity to continue investment in innovative research and development to drive future growth.

Olivier Legrain, chief executive officer of IBA, commented: “This collaboration with Cartu Foundation to bring proton therapy to Georgia further increases the reach of proton therapy around the world and demonstrates the appeal of IBA’s product offering. IBA’s Proteus®ONE solution is a unique and truly compact intensity modulated proton therapy (IMPT) system and, alongside its open gantry and track record of short installation time, is the solution of choice for an increasing number of hospitals globally. We look forward to working closely with the Cartu Foundation and the new Kutaisi International University to provide greater access to proton therapy for cancer patients in Georgia and the South Caucasus, and facilitate greater research into the modality such as FLASH irradiation and ARC Therapy in proton therapy.”

Alexander Tevzadze, rector of Kutaisi International University commented:Proton therapy is considered as a superior form of radiotherapy and represents a better treatment choice for many forms of cancer. We are excited to partner with IBA to bring proton therapy to Georgia as part of the proton therapy center at the Kutaisi International University. The unique configuration of IBA’s equipment and the additional cyclotron will offer us a comprehensive range of applications and will allow us to be at the forefront of proton therapy development and research, which perfectly fits the mission of Kutaisi International University. Also, our patients will be able to stay closer to home to receive treatment that was previously unavailable in the region.”

For more information: www.iba-worldwide.com

Related Content

The 15-ton compact accelerator is lifted into the David C. Pratt Cancer Center at Mercy St. Louis. (Photo: Business Wire)

The 15-ton compact accelerator is lifted into the David C. Pratt Cancer Center at Mercy St. Louis. (Photo: Business Wire)

News | Radiation Oncology | July 21, 2021
July 23, 2021 — Mevion Medical Systems announced that it has delivered the 15-ton compact accelerator to...
NeuroLogica joins forces with Massachusetts General Hospital to pilot OmniTom Elite with Photon Counting Detector (PCD) technology at patient point-of-care

NeuroLogica joins forces with Massachusetts General Hospital to pilot OmniTom Elite with Photon Counting Detector (PCD) technology at patient point-of-care. (Photo: Business Wire)

News | Computed Tomography (CT) | July 13, 2021
July 13, 2021 — NeuroLogica Corp.
 Mevion Medical Systems announced that the first proton center in the Mountain West, the Senator Orrin G. Hatch Center for Proton Therapy, has opened at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) and began treating patients on May 11 with the MEVION S250i Proton Therapy System.

The teams from HCI, U of U and Mevion gather to celebrate the center’s grand opening. Group from left to right: Bill Salter, Ph.D., Senior Director of Radiation Oncology, HCI and Professor and Chief of the Division of Medical Physics, U of U -- Robyn Walker, Sr. Director, Customer Success and Service Operations, Mevion -- James Cooley, Ph.D., Director of Advanced Development, Mevion -- Dennis Shrieve, M.D., Ph.D., Chair in Cancer Research, HCI and Chair of Department of Radiation Oncology, U of U -- Tina Yu, Ph.D., CEO, Mevion -- Michael Good, M.D., Interim President, U of U and Sr. VP for Health Sciences, U of U Health -- Ying Hitchcock, M.D., Professor and Medical Director, Department of Radiation Oncology, U of U. (Photo: Business Wire)

News | Proton Therapy | June 24, 2021
June 24, 2021 — Mevion Medical Systems announced that the first proton center in the Mountain West, the Senator Orrin
RaySearch Laboratories AB has launched the latest release of its widely adopted treatment planning system. RayStation 10B adds support for brachytherapy planning and a new GPU Monte Carlo algorithm, which typically cuts final dose computation times to less than five seconds.
News | Brachytherapy Systems | December 29, 2020
December 29, 2020 — RaySearch Laboratories AB has launched the latest release of its widely adopted treatment plannin
C-RAD has been selected as the partner to implement surface tracking technology for three proton cancer treatment centers in the U.S.
News | Proton Therapy | December 28, 2020
December 28, 2020 — C-RAD offers a specific version of its Catalyst System for use in...
Vinai Gondi, M.D., the Director of Research at the Northwestern Medicine Chicago Proton Center, Co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

Vinai Gondi, M.D., director of research at the Northwestern Medicine Chicago Proton Center, co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

News | Intensity Modulated Radiation Therapy (IMRT) | October 27, 2020
October 27, 2020 — A...
Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.
News | Proton Therapy | October 25, 2020
October 25, 2020 — Treating lung cancer patients with prot...
Be sure to register for the American Society for Radiation Oncology's (ASTRO) 62nd Annual Meeting, to be held October 24-28, 2020, via an interactive virtual platform. The meeting, Global Oncology: Radiation Therapy in a Changing World, will feature reports from the latest clinical trials; panels on global oncology, health disparities and the novel coronavirus; and an immersive attendee experience in a virtual convention center.
News | ASTRO | October 23, 2020
October 23, 2020 — Be sure to ...
IBA showcases how its Proteus solutions and its network of clinical and industrial partners are shaping the future of proton therapy
News | Proton Therapy | October 23, 2020
October 23, 2020 — IBA, a leading provider of proton thera...
RaySearch Laboratories AB will demo its latest advances in oncology software at the American Society for Radiation Oncology (ASTRO) 2020 Annual Meeting
News | Radiation Oncology | October 23, 2020
October 23, 2020 — RaySearch will present recent and upcoming enhancements, as well as new functionality, in...